Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
Lurasidone 80 mg	2 40 mg lurasidone tablets taken once/day
Placebo	Matching placebo to lurasidone 40 mg tablets taken once/day

Participant Flow:   Overall Study

	Lurasidone 80 mg	Placebo
STARTED	90	90
COMPLETED	52	47
NOT COMPLETED	38	43

Reporting Groups

	Description
Lurasidone 80 mg	2 40 mg lurasidone tablets taken once/day
Placebo	Matching placebo to lurasidone 40 mg tablets taken once/day

Baseline Measures

	Lurasidone 80 mg	Placebo	Total
Number of Participants   [units: participants]	90	90	180
Age   [units: years] Mean ± Standard Deviation	39.7  ± 9.91	41.9  ± 9.78	40.8  ± 9.88
Gender   [units: participants]
Female	22	20	42
Male	68	70	138

1.  Primary:

Change From Baseline to the End of the Double-blind Treatment in the BPRS (Brief Psychiatric Rating Scale) Total Score   [ Time Frame: Baseline and 6 weeks ]

2.  Secondary:

Change From Baseline to the End of the Double-blind Treatment in the PANSS (Positive and Negative Syndrome Scale) Scores   [ Time Frame: Baseline and 6 weeks ]

3.  Secondary:

Change From Baseline to the End of the Double-blind Treatment in the CGI-S (Clinical Global Impression of Severity) Scores   [ Time Frame: Baseline and 6 weeks ]

4.  Secondary:

Change From Baseline to the End of the Double-blind Treatment in the MADRS (Montgomery Asberg-Depression Scale) Scores   [ Time Frame: Baseline and 6 weeks ]